预约演示
更新于：2025-01-25
Prusogliptin
普卢格列汀
更新于：2025-01-25
概要
基本信息
原研机构 |
在研机构 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 中国 (2025-01-08), |
最高研发阶段(中国)批准上市 |
特殊审评特殊审批 (中国) |
登录后查看时间轴
结构/序列
分子式C16H25FN4O2 |
InChIKeyVQKSCYBKUIDZEI-STQMWFEESA-N |
CAS号1186426-66-3 |
关联
27
项与 普卢格列汀 相关的临床试验NCT05150626
An Open-label, Randomized, Three-period, Crossover, Single-dose Study to Evaluate the Effect of a Low-fat Meal and a Standard Meal on the Pharmacokinetics of DBPR108 in Healthy Subjects
CTR20213110
在健康受试者中评价低脂餐和标准餐对DBPR108片药代动力学影响的单剂量、随机、开放、三序列、三周期、交叉临床研究
NCT05146869
A Randomized, Open-Label, Parallel-Cohort, Single-dose and Multiple-dose Phase I Study of DBPR108 Tablets in Type 2 Diabetes Mellitus Patients
100 项与 普卢格列汀 相关的临床结果
登录后查看更多信息
100 项与 普卢格列汀 相关的转化医学
登录后查看更多信息
100 项与 普卢格列汀 相关的专利（医药）
登录后查看更多信息
8
项与 普卢格列汀 相关的文献（医药）2024-06-01EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Synthesis and clinical application of representative small-molecule dipeptidyl Peptidase-4 (DPP-4) inhibitors for the treatment of type 2 diabetes mellitus (T2DM)
Review
作者: Shao, Dong-Wei ; Zhao, Li-Jie ; Sun, Jin-Feng
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels, which can cause many diseases, including osteoporosis, fractures, arthritis, and foot complications. The inhibitors of dipeptidyl peptidase-4 (DPP-4), an enzyme involved in glucose metabolism regulation, are essential for managing Type 2 Diabetes Mellitus (T2DM). The inhibition of DPP-4 has become a promising treatment approach for T2DM because it can increase levels of active glucagon-like peptide-1 (GLP-1), leading to improved insulin secretion in response to glucose and reduced release of glucagon. The review commences by elucidating the role of DPP-4 in glucose homeostasis and its significance in T2DM pathophysiology. Furthermore, it presents the mechanism of action, preclinical pharmacodynamics, clinical efficacy, and toxicity profiles of small-molecule DPP-4 inhibitors across various clinical stages. This comprehensive review provides valuable insights into the synthesis and clinical application of DPP-4 inhibitors, serving as an invaluable resource for researchers, clinicians, and pharmaceutical professionals interested in diabetes therapeutics and drug development.
2024-04-01Diabetes, obesity & metabolism
Prusogliptin (DBPR108 ) monotherapy in treatment‐naïve patients with type 2 diabetes: A randomized, double‐blind, active and placebo‐controlled, phase 3 study
Article
作者: Yao, Lingli ; Cao, Mengya ; Zhang, Cheng ; Zhou, Deai ; Wang, Wei ; Guo, Xiaohui ; Ning, Tao ; Ma, Guoqing ; Zhang, Tianhao ; Chen, Ling ; Yuan, Jing ; Jia, Rui ; Huang, Yanli
Abstract:
Aim:
This study aimed to assess the efficacy and safety of prusogliptin (DBPR108), a novel and highly selective dipeptidyl peptidase‐4 inhibitor, in individuals with type 2 diabetes who had not been using glucose‐lowering agents regularly for the 8 weeks before the screening period.
Materials and Methods:
In this multicentre, randomized, double‐blind, phase 3 study, adult patients with type 2 diabetes were randomly assigned to receive either DBPR108 100 mg, sitagliptin 100 mg, or placebo once daily during the initial 24‐week double‐blind treatment period, followed by a 28‐week open‐label extension period during which all patients received DBPR108 100 mg once daily. The primary endpoint was the mean change in glycated haemoglobin (HbA1c) levels from baseline to week 24.
Results:
In total, 766 patients were enrolled and received DBPR108 100 mg (n = 462), sitagliptin 100 mg (n = 152), or placebo (n = 152). The mean age of all patients was 54.3 ± 10.5 years, with 58% being men. The median duration of type 2 diabetes was 0.38 (0.02, 2.65) years, and the mean HbA1c (SD) at baseline was 7.94% (0.62), 7.88% (0.61) and 7.83% (0.59) for DBPR108, sitagliptin and placebo groups, respectively. At week 24, the least square mean (SE) changes from baseline in HbA1c were −0.63% (0.04%) for DBPR108, −0.60% (0.07%) for sitagliptin and −0.02% (0.07%) for placebo. The mean treatment difference between DBPR108 and placebo was −0.61% (95% CI –0.77% to −0.44%), and between DBPR108 and sitagliptin was −0.03% (95% CI –0.19% to 0.13%). These results indicate that DBPR108 was superior to placebo and non‐inferior to sitagliptin. DBPR108 also significantly reduced fasting and postprandial plasma glucose levels and had little effect on body weight. The mean (SD) changes in HbA1c from baseline to week 52 were −0.50% (0.97%) for the DBPR108 group, −0.46% (0.96%) for the sitagliptin group and −0.41% (0.95%) for the placebo group. The incidence of adverse events was comparable across all three groups.
Conclusions:
DBPR108 showed superiority to placebo and non‐inferiority to sitagliptin in terms of glycaemic control over the initial 24 weeks in treatment‐naïve patients with type 2 diabetes. Furthermore, its efficacy was sustained for up to 52 weeks.
2024-02-01Current drug metabolism
A Phase I Clinical Study of the Pharmacokinetics and Safety of Prusogliptin
Tablets in Subjects with Mild to Moderate Hepatic Insufficiency and Normal
Liver Function
Article
作者: Zhang, Huiting ; Cai, Wen ; Zhang, Xueyuan ; Bian, Yicong ; Zhang, Hua ; Cui, Juanjuan ; Zhang, Xiaofang ; Miao, Liyan ; Zhao, Weifeng
Background::
Prusogliptin is a potent and selective DPP-4 inhibitor. In different animal models, Prusogliptin
showed potential efficacy in the treatment of type 2 diabetes. However, the knowledge of its pharmacokinetics
and safety in patients with liver dysfunction is limited.
Objectives::
The present study evaluated the pharmacokinetics and safety of Prusogliptin in subjects with mild
or moderate hepatic impairment compared with healthy subjects.
Methods::
According to the liver function of the subjects, we divided them into a mild liver dysfunction group,
a moderate liver dysfunction group and a normal liver function group. All subjects in three groups received a
single oral dose of Prusogliptin 100-mg tablets. Pharmacokinetics and safety index collection was carried out
before and after taking the drug. Plasma pharmacokinetics of Prusogliptin were evaluated, and geometric least-
-squares mean (GLSM) and associated 90% confidence intervals for insufficient groups versus the control
group were calculated for plasma exposures.
Results::
After a single oral administration of 100 mg of Prusogliptin tablets, the exposure level of Prusogliptin
in subjects with mild liver dysfunction was slightly higher than that in healthy subjects. The exposure level of
Prusogliptin was significantly increased in subjects with moderate liver dysfunction. There were no adverse
events in this study.
Conclusion::
The exposure level of Prusogliptin in subjects with liver dysfunction was higher than that in
healthy subjects. No participant was observed of adverse events. Prusogliptin tablets were safe and well tolerated
in Chinese subjects with mild to moderate liver dysfunction and normal liver function.
100 项与 普卢格列汀 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 2型糖尿病 | 中国 | 2025-01-08 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 肾功能不全 | 临床1期 | 中国 | 2021-06-15 | |
| 肝病 | 临床1期 | 中国 | 2021-06-09 | |
| 糖尿病 | 临床1期 | 中国台湾 | 2012-11-22 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 1,000 | Metformin+Prusogliptin | 構構膚鏇膚遞糧廠蓋衊(築製壓獵選淵鑰齋衊膚) = DBPR108片组显著优于安慰剂组 鏇鹽壓積願鑰築範鏇鬱 (餘餘鏇願構餘艱鑰構鏇 ) | 积极 | 2022-08-22 | ||
Metformin+Placebo | |||||||
临床2期 | 276 | 鑰鬱淵鑰願夢積獵齋壓(襯蓋積膚鑰壓醖顧構顧) = 遞醖製繭簾鹽艱築築窪 鏇範積鏇構鑰膚夢廠繭 (壓構鹽壓鏇窪艱醖艱顧 ) 更多 | 积极 | 2020-07-01 | |||
鑰鬱淵鑰願夢積獵齋壓(襯蓋積膚鑰壓醖顧構顧) = 艱繭夢選願簾壓廠廠窪 鏇範積鏇構鑰膚夢廠繭 (壓構鹽壓鏇窪艱醖艱顧 ) 更多 | |||||||
临床1期 | 32 | placebo+DBPR108 (Placebo) | 網積艱鏇願繭鏇襯艱製(製膚遞積憲鑰積製遞衊) = 醖遞窪顧憲顧鏇願襯願 齋觸壓醖積網憲壓構糧 (齋壓選餘蓋顧獵觸選遞, 衊顧構鹽觸築範鬱構膚 ~ 遞糧鑰繭鹽簾願鹽構艱) 更多 | - | 2014-08-28 | ||
(DBPR108 25 mg) | 網積艱鏇願繭鏇襯艱製(製膚遞積憲鑰積製遞衊) = 築廠顧糧選襯製糧簾衊 齋觸壓醖積網憲壓構糧 (齋壓選餘蓋顧獵觸選遞, 夢蓋構糧窪窪襯鹹淵壓 ~ 鬱簾蓋壓鹽製鏇製壓衊) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用